Answers are grounded in this paper and cite their sources.
Renal interstitial accumulation of monocytes/macrophages driven by chemoattractants such as monocyte chemoattractant protein-1 (MCP-1)/CCL2, is a characteristic feature of polycistic kidney diseases (PKD). It has been suggested that infiltrating inflammatory cells contribute to promoting cyst growth and renal function impairment in PKD. Recently, we reported that in experimental PKD in PCK rats, bindarit, an inhibitor of MCP-1, effectively decreased the excessive renal expression of MCP-1, and limited interstitial infiltrates of monocytes/macrophages. The anti-MCP-1 therapy displayed an important antiproteinuric effect associated with amelioration of podocyte structure. In this highlight we describe bindarit’s effects on the evolution of PKD in PCK rats and on the activity of the drug in cultured podocytes to explain its antiproteinuric effect.
No takes yet. Share an insight, caveat, or question.
A 2015 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: